Revenue Growth Leaders
VCEL is part of our revenue growth leaders stock screen, indicating it has strong recent and multi-year revenue growth.
VERICEL CORP (VCEL) Stock Price & Overview
NASDAQ:VCEL • US92346J1088
Current stock price
35.64 USD
+1.24 (+3.6%)
At close:
35.4 USD
-0.24 (-0.67%)
After Hours:
The current stock price of VCEL is 35.64 USD. Today VCEL is up by 3.6%. In the past month the price increased by 15.64%. In the past year, price decreased by -10.29%.
VCEL Key Statistics
52-Week Range28.95 - 45.97
Current VCEL stock price positioned within its 52-week range.
1-Month Range28.95 - 36
Current VCEL stock price positioned within its 1-month range.
- Market Cap
- 1.815B
- P/E
- 114.97
- Fwd P/E
- 80.79
- EPS (TTM)
- 0.31
- Dividend Yield
- N/A
VCEL Stock Performance
Today
+3.6%
1 Week
-0.11%
1 Month
+15.64%
3 Months
-5.84%
Longer-term
6 Months -1.87%
1 Year -10.29%
2 Years -22.30%
3 Years +13.11%
5 Years -42.90%
10 Years +1,137.50%
VCEL Stock Chart
VCEL Stock Screens
VCEL currently appears in the following ChartMill screener lists.
VCEL Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to VCEL. When comparing the yearly performance of all stocks, VCEL is a bad performer in the overall market: 78.28% of all stocks are doing better.
Chartmill TA Rating
Chartmill Setup Rating
VCEL Fundamental Analysis
ChartMill assigns a fundamental rating of 7 / 10 to VCEL. While VCEL belongs to the best of the industry regarding profitability, there are some minor concerns on its financial health.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
VCEL Earnings
On February 26, 2026 VCEL reported an EPS of 0.45 and a revenue of 92.92M. The company beat EPS expectations (13.12% surprise) and missed revenue expectations (-0.03% surprise).
Next Earnings DateMay 13, 2026
Last Earnings DateFeb 26, 2026
PeriodQ4 / 2025
EPS Reported$0.45
Revenue Reported92.918M
EPS Surprise 13.12%
Revenue Surprise -0.03%
VCEL Forecast & Estimates
14 analysts have analysed VCEL and the average price target is 56.54 USD. This implies a price increase of 58.63% is expected in the next year compared to the current price of 35.64.
For the next year, analysts expect an EPS growth of 42.31% and a revenue growth 17.82% for VCEL
Analysts
Analysts84.29
Price Target56.54 (58.64%)
EPS Next Y42.31%
Revenue Next Year17.82%
VCEL Groups
Sector & Classification
VCEL Financial Highlights
Over the last trailing twelve months VCEL reported a non-GAAP Earnings per Share(EPS) of 0.31. The EPS increased by 72.22% compared to the year before.
Income Statements
Revenue(TTM)276.26M
Net Income(TTM)16.52M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 5.98% | ||
| ROA | 3.39% | ||
| ROE | 4.66% | ||
| Debt/Equity | 0.01 |
Chartmill High Growth Momentum
EPS Q2Q%18.42%
Sales Q2Q%23.27%
EPS 1Y (TTM)72.22%
Revenue 1Y (TTM)16.45%
VCEL Ownership
Ownership
Inst Owners110.98%
Shares50.93M
Float50.18M
Ins Owners1.2%
Short Float %10.73%
Short Ratio8.86
VCEL Competitors/Peers
The largest stocks on the US markets in the "Biotechnology" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 13.4 | 355.432B | ||
| AMGN | AMGEN INC | 15.09 | 188.147B | ||
| GILD | GILEAD SCIENCES INC | 14.75 | 165.877B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.09 | 110.672B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.03 | 80.984B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 44.76 | 41.869B | ||
| INSM | INSMED INC | N/A | 31.046B | ||
| NTRA | NATERA INC | N/A | 28.508B | ||
| BIIB | BIOGEN INC | 11.44 | 27.573B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 26.65B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.41 | 25.108B | ||
| MRNA | MODERNA INC | N/A | 20.96B | ||
| INCY | INCYTE CORP | 12.23 | 19B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find more growth stocks the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About VCEL
Company Profile
Vericel Corp. engages in the research, product development, manufacture, and distribution of patient-specific, expanded cellular therapies for use in the treatment of patients with diseases. The company is headquartered in Cambridge, Massachusetts and currently employs 398 full-time employees. The firm is a provider of advanced therapies for the sports medicine and severe burn care markets. The company markets three products in the United States. MACI (autologous cultured chondrocytes on porcine collagen membrane) is an autologous-cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full-thickness burns greater than or equal to 30% of total body surface area. The firm also holds a license for North American rights to NexoBrid (anacaulase-bcdb), a biological orphan product containing proteolytic enzymes, which is indicated for the removal of eschar in adult and pediatric patients with deep partial thickness and/or full-thickness thermal burns.
Company Info
IPO: 1997-02-04
VERICEL CORP
64 Sidney St
Cambridge MASSACHUSETTS 02139 US
CEO: Dominick C. Colangelo
Employees: 398
Phone: 17349305555
VERICEL CORP / VCEL FAQ
What does VERICEL CORP do?
Vericel Corp. engages in the research, product development, manufacture, and distribution of patient-specific, expanded cellular therapies for use in the treatment of patients with diseases. The company is headquartered in Cambridge, Massachusetts and currently employs 398 full-time employees. The firm is a provider of advanced therapies for the sports medicine and severe burn care markets. The company markets three products in the United States. MACI (autologous cultured chondrocytes on porcine collagen membrane) is an autologous-cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full-thickness burns greater than or equal to 30% of total body surface area. The firm also holds a license for North American rights to NexoBrid (anacaulase-bcdb), a biological orphan product containing proteolytic enzymes, which is indicated for the removal of eschar in adult and pediatric patients with deep partial thickness and/or full-thickness thermal burns.
What is the current price of VCEL stock?
The current stock price of VCEL is 35.64 USD. The price increased by 3.6% in the last trading session.
Does VCEL stock pay dividends?
VCEL does not pay a dividend.
What is the ChartMill technical and fundamental rating of VCEL stock?
VCEL has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 7 out of 10.
Which stock exchange lists VCEL stock?
VCEL stock is listed on the Nasdaq exchange.
How many employees does VERICEL CORP have?
VERICEL CORP (VCEL) currently has 398 employees.
Can you provide the short interest for VCEL stock?
The outstanding short interest for VERICEL CORP (VCEL) is 10.73% of its float.